ライフサイエンスコーパス: Velcade

1 the proteasome inhibitor bortezomib (PS-341, Velcade).

2 easome inhibitors lactacystin or bortezomib (Velcade).

3 ulation during challenge with tunicamycin or Velcade.

4 (Uros(P248Q/P248Q)) treated with bortezomib (Velcade), a clinically approved proteasome inhibitor, we

5 Bortezomib (PS-341, Velcade), a potent TRAIL-sensitizing agent, increased se

6 4-HPR was found to be synergistic with Velcade, a proteasome inhibitor.

7 on of the proteasome with bortezomib (PS-341/Velcade) also rescued CFTR, but with less efficiency, an

8 e proteasome inhibitor PS-341 (bortezomib or Velcade), an approved drug for treatment of patients wit

9 portant therapy for neoplastic disease, with velcade, an organoboron compound used extensively in mul

10 ng synthesis of the alkyl boronic acid drugs Velcade and Ninlaro as well as a boronic acid version of

11 icantly potentiated the apoptotic effects of Velcade and thalidomide in MM cells.

12 ibitor NPI-0052 is distinct from bortezomib (Velcade) and, importantly, triggers apoptosis in multipl

13 final analysis of the phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple Myeloma:

14 ogy target following the clinical success of VELCADE (bortezomib) for injection for the treatment of

15 proved proteasome inhibitor bortezomib (BZM; Velcade) counteracts the cytokine-dependent induction of

16 The proteasome inhibitor bortezomib (Velcade) effectively eradicates multiple myeloma (MM) ce

17 used to treat patients such as melphalan and VELCADE efficiently kills malignant plasmocytes in vivo.

18 ly approved 20S inhibitor bortezomib (PS341; Velcade), focusing on those overexpressing estrogen rece

19 dministration approval of bortezomib (PS341, Velcade) for the treatment of refractory multiple myelom

20 Studies with bortezomib (VELCADE, formerly known as PS-341) and other proteasome

21 Bortezomib (Velcade, formerly known as PS-341) is a boronic acid dip

22 shown that proteasome inhibitor bortezomib (Velcade, formerly PS-341) can overcome conventional drug

23 ith the approval of the proteasome inhibitor Velcade in 2003 by the FDA.

24 ted the apoptotic effects of thalidomide and Velcade in MM cells.

25 portantly, that is distinct from bortezomib (Velcade) in its chemical structure, effects on proteasom

26 hibition of the proteasome by lactacystin or Velcade increases the levels of R555W mis-sense mutated

27 e inhibitor bortezomib (also known as PS-341/Velcade) is a dipeptidyl boronic acid that has recently

28 Bortezomib (PS-341, Velcade) is a potent and selective inhibitor of the prot

29 The proteasome inhibitor bortezomib (Velcade) is a promising new agent for bladder cancer the

30 Bortezomib (Velcade) is a reversible proteasome inhibitor that is ap

31 The proteasome inhibitor bortezomib (Velcade) is known to trigger endoplasmic reticulum (ER)

32 PS-341 (also called Bortezomib or Velcade) is the first proteasome inhibitor approved for

33 Bortezomib (Velcade) is used widely for the treatment of various hum

34 , NJ), and the proteasome inhibitor, PS 341 (Velcade; Millenium, Cambridge, MA), all of which not onl

35 The proteasome inhibitor bortezomib (PS-341, Velcade; Millennium Pharmaceuticals, Cambridge, MA), app

36 the proteasome inhibitor bortezomib (PS-341, Velcade) observed in clinical trials of patients with re

37 treatment with either a proteasome inhibitor Velcade or an immunosuppressant cyclosporine A.

38 PS-341, also known as Velcade or Bortezomib, represents a new class of antican

39 Bortezomib (Velcade; previously called PS-341) is a potent and speci

40 36) with a proteasome inhibitor (bortezomib, Velcade, PS-341) would enhance myeloma-cell killing.

41 Bortezomib (Velcade, PS341) was licensed in 2003 as a first-in-class

42 nants that confer sensitivity to bortezomib (Velcade (R); PS-341).

43 ved proteasome-inhibiting drugs, bortezomib (Velcade(R)), carfilzomib (Kyprolis(R)), and ixazomib (Ni

44 her proteasome inhibitors (e.g., Bortezomib (VELCADE trade mark bortezomib or injection), lactacystin